AIDS
Twice-Yearly Lenacapavir 100% Effective in Preventing HIV Among Cisgender Women
An interim analysis of PURPOSE 1 found twice-yearly lenacapavir was superior to once-daily oral FTC/TDF in ...
JULY 24, 2024
Should Doxy-PEP Be U.S. Strategy Amid Syphilis Surge?
Infectious disease pharmacists working in emergency departments, HIV/AIDS clinics and other areas of care where ...
NOVEMBER 8, 2023
Sometimes Even ‘Detectable’ Can Mean Untransmissible
People living with HIV who maintain low—but still detectible—levels of the virus but adhere to their ...
JULY 25, 2023
Fostemsavir Bright Spot in Improving Virologic Suppression in Resistant HIV Patients
Rates of virologic suppression and immunologic response increased from weeks 48 to 96 in a phase 3 clinical trial ...
JULY 25, 2019
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
FDA Expands Indication for Truvada for PrEP Among Adolescents
The FDA granted a new indication for Gilead's Truvada to reduce the risk for sexually acquired HIV-1 in at-risk ...
MAY 15, 2018
